| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/HIV.12012 |
| P698 | PubMed publication ID | 23298380 |
| P2093 | author name string | B Clotet | |
| M Stevens | |||
| A Antinori | |||
| C Hicks | |||
| J Fourie | |||
| G Herrera | |||
| A M Mills | |||
| K Boven | |||
| S Vanveggel | |||
| ECHO and THRIVE study groups | |||
| J V Madruga | |||
| P2860 | cites work | High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations | Q27649731 |
| Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design | Q27661231 | ||
| Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients | Q31977562 | ||
| Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s) | Q34216364 | ||
| Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring | Q34464997 | ||
| Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens | Q34647483 | ||
| Adherence to HAART Regimens | Q35123915 | ||
| Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. | Q36198650 | ||
| Quality of life among HIV-infected patients in Brazil after initiation of treatment | Q37349903 | ||
| Recent advances in DAPYs and related analogues as HIV-1 NNRTIs | Q37818380 | ||
| Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients | Q38959219 | ||
| Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort | Q39669125 | ||
| TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. | Q39771532 | ||
| Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeks | Q43172781 | ||
| Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial | Q43238337 | ||
| Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial | Q43300648 | ||
| Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz | Q44238575 | ||
| Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial | Q44513458 | ||
| Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence | Q44751490 | ||
| Quality of life and physical functioning in HIV-infected individuals receiving antiretroviral therapy in KwaZulu-Natal, South Africa | Q44804297 | ||
| Factors associated with efavirenz discontinuation in a large community-based sample of patients | Q44956373 | ||
| Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials | Q45414505 | ||
| HIV patient insight on adhering to medication: a qualitative analysis | Q46073238 | ||
| Depressive symptoms and exposure to efavirenz in West African HIV-infected adults | Q46127982 | ||
| Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients | Q46454446 | ||
| Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients | Q46743851 | ||
| Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals | Q46803644 | ||
| Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort | Q46880626 | ||
| Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study | Q48485316 | ||
| Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles | Q48493585 | ||
| Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. | Q50788638 | ||
| Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. | Q51547763 | ||
| Underrecognition of clinically significant side effects in depressed outpatients. | Q51852537 | ||
| Factors that affect the quality of life of prison inmates on antiretroviral treatment. | Q51915968 | ||
| Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. | Q51931076 | ||
| Patient preferences among third agent HIV medications: a US and German perspective | Q57117642 | ||
| P433 | issue | 7 | |
| P921 | main subject | efavirenz | Q422645 |
| P304 | page(s) | 391-400 | |
| P577 | publication date | 2013-01-09 | |
| P1433 | published in | HIV Medicine | Q15756376 |
| P1476 | title | Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks | |
| P478 | volume | 14 |
| Q54211761 | A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population. |
| Q38272654 | Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis |
| Q36282702 | HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014. |
| Q38976612 | Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz |
| Q42592784 | Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz |
| Q39004638 | Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art. |
| Q52774286 | Neurological Complications of HIV Infection. |
| Q35652019 | Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial |
| Q58254289 | Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 t |
| Q92730184 | Prediction Model of Pre-treatment HIV RNA Levels in Naïve Thai HIV-infected Patients: Application for Resource-limited Settings |
| Q40513800 | Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen. |
| Q40132756 | Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study |
| Q38802093 | Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients |
| Q92797562 | The role of rilpivirine in Southern Africa |
| Q54570876 | [Safety profile of rilpivirine: general and neuropsychiatric tolerability, safety in patients with hepatitis B or C viruses, and lipid profile]. |
Search more.